Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Boyd

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
Lancet (London, England)|July 6, 2004
Creation of a drug fund for post-clinical trial access to antiretroviralsJintanat Ananworanich, Theshinee Cheunyam, Somsong Teeratakulpisarn, et al.
BMJ Open|August 26, 2019
Sociodemographic, lifestyle and metabolic predictors of all-cause mortality in a cohort of community-dwelling population: an 18-year follow-up of the North West Adelaide Health StudyYohannes Adama Melaku, Tiffany K Gill, Sarah L Appleton, et al.
Health Promotion Journal of Australia : Official Journal of Australian Association of Health Promotion Professionals|September 12, 2021
Barriers to digital health services among people living in areas of socioeconomic disadvantage: Research from hospital diabetes and antenatal clinicsToby Freeman, Matthew Fisher, Kristen Foley, et al.
Plos One|June 27, 2014
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialAmit C Achhra, Mark A Boyd, Matthew G Law, et al.
Heart, Lung & Circulation|May 7, 2021
Role of Indices Incorporating Power, Force and Time in AF Ablation: A Systematic Review of LiteratureThirakan Rattanakosit, Kyle Franke, Dian Andina Munawar, et al.
Plos One|March 5, 2013
The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South AfricaKaren Schneider, Chidi Nwizu, Richard Kaplan, et al.
Public Health Research & Practice|June 9, 2021
Capturing the social determinants of health at the individual level: a pilot studyKate E Neadley, Gai McMichael, Toby Freeman, et al.
AIDS Care|August 5, 2024
Perceptions of nicotine vaping products among Australians living with HIVStephanie Edwards, Cheneal Puljević, Judith A Dean, et al.
Plos One|July 11, 2013
Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific regionStephen Wright, Mark A Boyd, Evy Yunihastuti, et al.
International Journal of Environmental Research and Public Health|July 19, 2017
Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who SmokeStephanie Bell, Judith Dean, Charles Gilks, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
Lancet (London, England)|July 6, 2004
Creation of a drug fund for post-clinical trial access to antiretroviralsJintanat Ananworanich, Theshinee Cheunyam, Somsong Teeratakulpisarn, et al.
BMJ Open|August 26, 2019
Sociodemographic, lifestyle and metabolic predictors of all-cause mortality in a cohort of community-dwelling population: an 18-year follow-up of the North West Adelaide Health StudyYohannes Adama Melaku, Tiffany K Gill, Sarah L Appleton, et al.
Health Promotion Journal of Australia : Official Journal of Australian Association of Health Promotion Professionals|September 12, 2021
Barriers to digital health services among people living in areas of socioeconomic disadvantage: Research from hospital diabetes and antenatal clinicsToby Freeman, Matthew Fisher, Kristen Foley, et al.
Plos One|June 27, 2014
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialAmit C Achhra, Mark A Boyd, Matthew G Law, et al.
Heart, Lung & Circulation|May 7, 2021
Role of Indices Incorporating Power, Force and Time in AF Ablation: A Systematic Review of LiteratureThirakan Rattanakosit, Kyle Franke, Dian Andina Munawar, et al.
Plos One|March 5, 2013
The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South AfricaKaren Schneider, Chidi Nwizu, Richard Kaplan, et al.
Public Health Research & Practice|June 9, 2021
Capturing the social determinants of health at the individual level: a pilot studyKate E Neadley, Gai McMichael, Toby Freeman, et al.
AIDS Care|August 5, 2024
Perceptions of nicotine vaping products among Australians living with HIVStephanie Edwards, Cheneal Puljević, Judith A Dean, et al.
Plos One|July 11, 2013
Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific regionStephen Wright, Mark A Boyd, Evy Yunihastuti, et al.
International Journal of Environmental Research and Public Health|July 19, 2017
Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who SmokeStephanie Bell, Judith Dean, Charles Gilks, et al.
Pageof 10